QR код

Avidity engineering of human heavy-chain-only antibodies mitigates neutralization resistance of SARS-CoV-2 variants

Emerging SARS-CoV-2 variants have accrued mutations within the spike protein rendering most therapeutic monoclonal antibodies against COVID-19 ineffective. Hence there is an unmet need for broad-spectrum mAb treatments for COVID-19 that are more resistant to antigenically drifted SARS-CoV-2 variants...

Повний опис

Збережено в:
Автори: Wenjuan Du, Rick Janssens, Anna Z. Mykytyn, Wentao Li, Dubravka Drabek, Rien van Haperen, Marianthi Chatziandreou, Melanie Rissmann, Joline van der Lee, Melissa van Dortmondt, Itziar Serna Martin, Frank J. M. van Kuppeveld, Daniel L. Hurdiss, Bart L. Haagmans, Frank Grosveld, Berend-Jan Bosch
Формат: Artigo
Мова:Inglês
Опубліковано: Frontiers Media S.A. 2023-02-01
Серія:Frontiers in Immunology
Предмети:
heavy-chain-only antibody
avidity
SARS-CoV-2
antibody-mediated neutralization
neutralization escape
Онлайн доступ:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1111385/full
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!

Схожі ресурси